COSCIENS Biopharma Inc.
CSCI
$3.46
-$0.09-2.54%
NASDAQ
| 12/31/2024 | 06/30/2024 | 03/31/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 20.10% | 67.89% | -20.43% | -20.43% | 11.31% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.10% | 67.89% | -20.43% | -20.43% | 11.31% |
| Cost of Revenue | -68.47% | 155.13% | -17.47% | -17.47% | 7,817.65% |
| Gross Profit | 261.08% | 2.76% | -23.91% | -23.91% | -152.26% |
| SG&A Expenses | 555.39% | 149.51% | -313.34% | -313.34% | -129.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 264.38% | 143.10% | -106.77% | -106.77% | -163.78% |
| Operating Income | -151.70% | -237.07% | 713.32% | 713.32% | 269.20% |
| Income Before Tax | -186.28% | -73.15% | -399.45% | -399.45% | 152.58% |
| Income Tax Expenses | 222.26% | -101.70% | -428.21% | -428.21% | -- |
| Earnings from Continuing Operations | -190.57% | -65.35% | -391.58% | -391.58% | 159.69% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -190.57% | -65.35% | -391.58% | -391.58% | 159.69% |
| EBIT | -151.70% | -237.07% | 713.32% | 713.32% | 269.20% |
| EBITDA | -144.44% | -349.20% | 29,166.67% | 29,166.67% | 294.35% |
| EPS Basic | -208.06% | -37.53% | -391.64% | -391.64% | 119.34% |
| Normalized Basic EPS | -151.96% | -44.01% | 724.57% | 724.57% | 150.20% |
| EPS Diluted | -208.15% | -37.53% | -391.64% | -391.64% | 119.32% |
| Normalized Diluted EPS | -151.96% | -44.01% | 724.57% | 724.57% | 150.20% |
| Average Basic Shares Outstanding | -16.19% | 20.22% | 0.01% | 0.01% | 208.65% |
| Average Diluted Shares Outstanding | -16.19% | 20.22% | 0.01% | 0.01% | 208.65% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |